These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 28947112)

  • 1. Medical management of motor manifestations of Huntington disease.
    McCusker EA; Loy CT
    Handb Clin Neurol; 2017; 144():141-150. PubMed ID: 28947112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature.
    Chen JJ; Ondo WG; Dashtipour K; Swope DM
    Clin Ther; 2012 Jul; 34(7):1487-504. PubMed ID: 22749259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetrabenazine and movement disorders.
    Asher SW; Aminoff MJ
    Neurology; 1981 Aug; 31(8):1051-4. PubMed ID: 6455607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dystonia-predominant adult-onset Huntington disease: association between motor phenotype and age of onset in adults.
    Louis ED; Anderson KE; Moskowitz C; Thorne DZ; Marder K
    Arch Neurol; 2000 Sep; 57(9):1326-30. PubMed ID: 10987900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Huntington's disease: present treatments and future therapeutic modalities.
    Bonelli RM; Wenning GK; Kapfhammer HP
    Int Clin Psychopharmacol; 2004 Mar; 19(2):51-62. PubMed ID: 15076012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is non-recognition of choreic movements in Huntington disease always pathological?
    Justo D; Charles P; Daunizeau J; Delmaire C; Gargiulo M; Hahn-Barma V; Naccache L; Durr A
    Neuropsychologia; 2013 Mar; 51(4):748-59. PubMed ID: 23262076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New symptomatic therapies for Huntington disease.
    Deb A; Frank S; Testa CM
    Handb Clin Neurol; 2017; 144():199-207. PubMed ID: 28947118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. State-of-the-art pharmacological approaches to reduce chorea in Huntington's disease.
    Gibson JS; Claassen DO
    Expert Opin Pharmacother; 2021 Jun; 22(8):1015-1024. PubMed ID: 33550875
    [No Abstract]   [Full Text] [Related]  

  • 9. Involuntary movement disorders.
    Still CN
    Neurol Clin; 1984 Feb; 2(1):71-89. PubMed ID: 6239089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease.
    Coppen EM; Roos RA
    Drugs; 2017 Jan; 77(1):29-46. PubMed ID: 27988871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic approaches to the treatment of Huntington's disease.
    Venuto CS; McGarry A; Ma Q; Kieburtz K
    Mov Disord; 2012 Jan; 27(1):31-41. PubMed ID: 21997232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of tetrabenazine on extrapyramidal movement disorders.
    Dalby MA
    Br Med J; 1969 May; 2(5654):422-3. PubMed ID: 4238453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An MDS Evidence-Based Review on Treatments for Huntington's Disease.
    Ferreira JJ; Rodrigues FB; Duarte GS; Mestre TA; Bachoud-Levi AC; Bentivoglio AR; Burgunder JM; Cardoso F; Claassen DO; Landwehrmeyer GB; Kulisevsky J; Nirenberg MJ; Rosser A; Roth J; Seppi K; Slawek J; Furr-Stimming E; Tabrizi SJ; Walker FO; Vandenberghe W; Costa J; Sampaio C
    Mov Disord; 2022 Jan; 37(1):25-35. PubMed ID: 34842303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine depleters in the treatment of hyperkinetic movement disorders.
    Jankovic J
    Expert Opin Pharmacother; 2016 Dec; 17(18):2461-2470. PubMed ID: 27819145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutics of disordered movement.
    Sears ES
    Am Fam Physician; 1977 Sep; 16(3):145-54. PubMed ID: 143204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches?
    Killoran A; Biglan KM
    Mov Disord; 2014 Sep; 29(11):1404-13. PubMed ID: 25164707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pridopidine for the treatment of Huntington's disease.
    Shannon KM
    Expert Opin Investig Drugs; 2016; 25(4):485-92. PubMed ID: 26881734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An experimental model for Huntington's chorea?
    Zeef DH; Jahanshahi A; Vlamings R; Casaca-Carreira J; Santegoeds RG; Janssen ML; Oosterloo M; Temel Y
    Behav Brain Res; 2014 Apr; 262():31-4. PubMed ID: 24412685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tetrabenazine in the treatment of hyperkinetic movement disorders.
    Kenney C; Jankovic J
    Expert Rev Neurother; 2006 Jan; 6(1):7-17. PubMed ID: 16466307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physician perceptions of pharmacologic treatment options for chorea associated with Huntington disease in the United States.
    Sung VW; Iyer RG; Gandhi SK; Shah-Manek B; DiBonaventura M; Abler V; Claassen DO
    Curr Med Res Opin; 2018 Apr; 34(4):643-648. PubMed ID: 29383957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.